Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11145765 | 0.82 | GRM5 (0.46) | ALDH1A1KDM4EMAPK1HSD17B10MAPT | |
| SCHEMBL18361622 | 0.80 | S1PR4 (0.40) | ALDH1A1KDM4EMAPK1HSD17B10MAPT | |
| SCHEMBL27361645 | 0.79 | MAPT (0.40) | ALDH1A1KDM4EMAPK1HSD17B10MAPT | |
| SCHEMBL17150201 | 0.77 | NPC1 (0.39) | ALDH1A1KDM4EMAPK1HSD17B10MAPT | |
| SCHEMBL11608373 | 0.77 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10GAATSHR | |
| SCHEMBL11479180 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPK1HSD17B10MAPT | |
| SCHEMBL5431429 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPK1MAPTGAA | |
| SCHEMBL6829758 | 0.73 | NFE2L2 (0.37) | ALDH1A1MAPTTSHRS1PR4 | |
| SCHEMBL11166949 | 0.73 | TDP1 (0.53) | ALDH1A1KDM4EHSD17B10MAPTTSHR | |
| SCHEMBL30522860 | 0.73 | MAPT (0.46) | MAPK1MAPTGAASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | ALDH1A1 1592/4885KDM4E 1493/4885MAPK1 91/4885 |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALDH1A1 1592/4885KDM4E 1493/4885MAPK1 91/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALDH1A1 1592/4885KDM4E 1493/4885MAPK1 91/4885 |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALDH1A1 1592/4885KDM4E 1493/4885MAPK1 91/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | ALDH1A1 1592/4885KDM4E 1493/4885MAPK1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.